Literature DB >> 23609032

Adenovirus arming human IL-24 inhibits neuroblastoma cell proliferation in vitro and xenograft tumor growth in vivo.

Baobiao Zhuo1, Rong Wang, Yiyu Yin, Hongwei Zhang, Tongsheng Ma, Fengli Liu, Hui Cao, Yingchun Shi.   

Abstract

Data have increasingly shown that interlukin-24 (IL-24) has growth suppression activity and can induce apoptosis in a broad spectrum of tumor cells. However, the therapeutic effect of IL-24 on human neuroblastoma has rarely been explored. In this study, we used a human neuroblastoma cell line (SH-SY5Y) to reveal the effect of adenovirus-mediated IL-24 (Ad-IL24) gene therapy for neuroblastoma. We showed that Ad-IL24 effectively inhibited the proliferation of SH-SY5Y cells in vitro by conspicuously inducing apoptosis. To further explore the molecular mechanism by which Ad-IL24 induced apoptosis in SH-SY5Y tumor cells, we found that Ad-IL24 increased the expression of Bax and promoted the activation of caspase-3, while decreasing Bcl-2 levels. We also demonstrated that Ad-IL24 significantly inhibited tumor growth in vivo in a xenograft neuroblastoma tumor in athymic nude mice. In summary, Ad-IL24 overexpression exerted potent antitumor activity via inducing apoptosis in neuroblastoma cells. Therefore, IL-24 has the potential to serve as an agent for gene therapy in the treatment of neuroblastoma.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23609032     DOI: 10.1007/s13277-013-0792-1

Source DB:  PubMed          Journal:  Tumour Biol        ISSN: 1010-4283


  26 in total

Review 1.  Neuroblastoma as a neurobiological disease.

Authors:  N F Schor
Journal:  J Neurooncol       Date:  1999-01       Impact factor: 4.130

Review 2.  Progress towards personalized therapeutics: biologic- and risk-directed therapy for neuroblastoma.

Authors:  William Clay Gustafson; Katherine K Matthay
Journal:  Expert Rev Neurother       Date:  2011-10       Impact factor: 4.618

3.  Neuroblastoma: changing incidence and survival in young people aged 0-24 years. A report from the North of England Young Persons' Malignant Disease Registry.

Authors:  S J Cotterill; L Parker; L More; A W Craft
Journal:  Med Pediatr Oncol       Date:  2001-01

4.  Poor treatment outcome of neuroblastoma and other peripheral nerve cell tumors may be related to under usage of radiotherapy and socio-economic disparity: a US SEER data analysis.

Authors:  Rex Cheung
Journal:  Asian Pac J Cancer Prev       Date:  2012

Review 5.  Recent advances in neuroblastoma.

Authors:  John M Maris
Journal:  N Engl J Med       Date:  2010-06-10       Impact factor: 91.245

6.  Genomic structure, chromosomal localization and expression profile of a novel melanoma differentiation associated (mda-7) gene with cancer specific growth suppressing and apoptosis inducing properties.

Authors:  E Y Huang; M T Madireddi; R V Gopalkrishnan; M Leszczyniecka; Z Su; I V Lebedeva; D Kang; H Jiang; J J Lin; D Alexandre; Y Chen; N Vozhilla; M X Mei; K A Christiansen; F Sivo; N I Goldstein; A B Mhashilkar; S Chada; E Huberman; S Pestka; P B Fisher
Journal:  Oncogene       Date:  2001-10-25       Impact factor: 9.867

Review 7.  Melanoma differentiation associated gene-7 (mda-7)/IL-24: a 'magic bullet' for cancer therapy?

Authors:  Devanand Sarkar; Irina V Lebedeva; Pankaj Gupta; Luni Emdad; Moira Sauane; Paul Dent; David T Curiel; Paul B Fisher
Journal:  Expert Opin Biol Ther       Date:  2007-05       Impact factor: 4.388

8.  Comparison of two different conditioning regimens before autologous transplantation for children with high-risk neuroblastoma.

Authors:  Maria Antonietta DE Ioris; Benedetta Contoli; Alessandro Jenkner; Maria Debora DE Pasquale; Annalisa Serra; Luigi DE Sio; Rosanna Pessolano; Maria Carmen Garganese; Alessandro Crocoli; Teresa Corneli; Renata Boldrini; Aurora Castellano
Journal:  Anticancer Res       Date:  2012-12       Impact factor: 2.480

9.  Fetal and neonatal neuroblastoma: retrospective review of 271 cases.

Authors:  Hart Isaacs
Journal:  Fetal Pediatr Pathol       Date:  2007 Jul-Aug       Impact factor: 0.958

Review 10.  Bcl-2-regulated apoptosis: mechanism and therapeutic potential.

Authors:  Jerry M Adams; Suzanne Cory
Journal:  Curr Opin Immunol       Date:  2007-07-12       Impact factor: 7.486

View more
  7 in total

1.  Interleukin-24 inhibits osteosarcoma cell migration and invasion via the JNK/c-Jun signaling pathways.

Authors:  Baobiao Zhuo; Yingchun Shi; Haihui Qin; Qingzeng Sun; Zhengwei Li; Fengfei Zhang; Rong Wang; Xiaodong Wang
Journal:  Oncol Lett       Date:  2017-04-05       Impact factor: 2.967

2.  Differentiated Human SH-SY5Y Cells Provide a Reductionist Model of Herpes Simplex Virus 1 Neurotropism.

Authors:  Mackenzie M Shipley; Colleen A Mangold; Chad V Kuny; Moriah L Szpara
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

3.  mda-7/IL-24 Induces Cell Death in Neuroblastoma through a Novel Mechanism Involving AIF and ATM.

Authors:  Praveen Bhoopathi; Nathaniel Lee; Anjan K Pradhan; Xue-Ning Shen; Swadesh K Das; Devanand Sarkar; Luni Emdad; Paul B Fisher
Journal:  Cancer Res       Date:  2016-04-13       Impact factor: 12.701

4.  Germline mutations and blood malignancy (Review).

Authors:  Yuping Gong; Jili Deng; Xia Wu
Journal:  Oncol Rep       Date:  2020-11-11       Impact factor: 3.906

5.  Combination therapy with F5/35 fiber chimeric conditionally replicative adenoviruses expressing IL-24 enhances the antitumor effect of temozolomide against melanoma.

Authors:  Ming Yang; Chunsheng Yang; Yingkai Tao; Jianqin Tang; Qian Huang; Wenwen Guo; Shouxin Feng; Aijun Jiang; Xifeng Xu; Guan Jiang; Yanqun Liu
Journal:  Cancer Med       Date:  2018-11-08       Impact factor: 4.452

6.  Oncolytic adenovirus: A tool for reversing the tumor microenvironment and promoting cancer treatment (Review).

Authors:  Xiaoxi Wang; Liping Zhong; Yongxiang Zhao
Journal:  Oncol Rep       Date:  2021-03-24       Impact factor: 3.906

7.  Targeting activating mutations of EZH2 leads to potent cell growth inhibition in human melanoma by derepression of tumor suppressor genes.

Authors:  Jessamy C Tiffen; Dilini Gunatilake; Stuart J Gallagher; Kavitha Gowrishankar; Anja Heinemann; Carleen Cullinane; Ken Dutton-Regester; Gulietta M Pupo; Dario Strbenac; Jean Y Yang; Jason Madore; Graham J Mann; Nicholas K Hayward; Grant A McArthur; Fabian V Filipp; Peter Hersey
Journal:  Oncotarget       Date:  2015-09-29
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.